Renin-angiotensin-system-acting agents for COVID-19 - living meta-analysis of clinical studies

meta|evidence COVID-19

Living systematic review and meta-analysis

vs. potential COVID-19 treatments
vs. control
vs. placebo
vs. standard of care
vs. miscellaneous
vs. calcium channel blocker
vs. Renin-angiotensin-system-acting agents
vs. continuation of ACEI/ARB

All
COVID 19 hospitalized
COVID 19 all comers
COVID-19 mild to moderate
COVID-19 severe or critically
COVID 19 outpatients
COVID-19 (hospitalized or not)
COVID-19 prophylaxis (children)
COVID-19 prophylaxis (excluding children)
infections other than COVID-19
Long COVID-19
preventing respiratory virus transmission
root
secondary prevention

Studies
Mapping
Meta-analysis
Excluded 0

table network network 2

display ongoing demontrated benefit only

popup

University of Minnesota, 2021 NCT04311177

angiotensin receptor blockers (ARBs) vs. placebo

COVID 19 outpatients

ACEI-COVID (Bauer), 2021 NCT04353596

discontinuation of ACEI/ARB vs. continuation of ACEI/ARB

COVID 19 outpatients

NCT04360551, 0 NCT04360551

Renin-angiotensin-system-acting agents vs. placebo

COVID 19 outpatients

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -

Extraction panel open

An extraction panel is open